Dr Terence Friedlander, a medical oncologist at the San Francisco Medical Center, shared insights on the current and future management of metastatic urothelial cancer. He discussed promising additional 3-month follow-up data from cohort K of the EV-103 study, which included cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who had not received prior treatment.
With the educational support of:
